Department of Medicinal Chemistry, Piramal Enterprises Limited, Goregaon (E), Mumbai 400 063, Maharashtra, India.
Eur J Med Chem. 2013 Jul;65:337-47. doi: 10.1016/j.ejmech.2013.05.006. Epub 2013 May 14.
Biphenyl carboxylic acids, exemplified by compound 5, are known potent inhibitors of diacylglycerol acyltransferase, DGAT1, an enzyme involved in the final committed step of triglyceride biosynthesis. We have synthesized and evaluated 2-phenylthiazole, 4-phenylthiazole, and 5-phenylthiazole analogs as DGAT1 inhibitors. The 5-phenylthiazole series exhibited potent DGAT1 inhibition when evaluated using an in vitro enzymatic assay and an in vivo fat tolerance test in mice. Compound 33 (IC50 = 23 nM) exhibiting promising oral pharmacokinetic parameters (AUCinf = 7058 ng h/ml, T1/2 = 0.83 h) coupled with 87 percent reduction of plasma triglycerides in vivo may serve as a lead for developing newer anti-obesity agents.
联苯羧酸类化合物,以化合物 5 为例,是二酰基甘油酰基转移酶(DGAT1)的有效抑制剂,DGAT1 是甘油三酯生物合成的最后一个关键酶。我们已经合成并评估了 2-苯基噻唑、4-苯基噻唑和 5-苯基噻唑类似物作为 DGAT1 抑制剂。在体外酶促测定和体内小鼠耐脂性试验中,5-苯基噻唑系列表现出很强的 DGAT1 抑制作用。化合物 33(IC50 = 23 nM)具有良好的口服药代动力学参数(AUCinf = 7058 ng h/ml,T1/2 = 0.83 h),并且在体内能使血浆甘油三酯降低 87%,可能成为开发新型抗肥胖药物的先导化合物。